Lung cancer, despite modern trends in the development of medical oncology and science, remains one of the key tasks of clinical medicine. On the one hand, this is due to the fact that the overwhelming number of patients at the time of initial diagnosis have an unresectable/inoperable stage of the disease, on the other hand, the latest predictive indicators in the world still indicate a high incidence of morbidity and mortality in terms of the structure of cancer incidence. In this regard, there is an urgent need to find alternative ways to treat the malignant process, including drug therapy. Drug therapy for lung cancer in the world today is represented by an extensive list of optional cytostatics, targeted agents, and immunoages.

Thus, in the Russian Federation, over 63 thousand new cases of lung cancer are detected annually and about 53 thousand in men. The average annual growth rate was 0.06% for men and 1.99% for women for 2021 and the number of newly identified cases is steadily growing. In the Republic of Kazakhstan, these data are statistically different from those of the Russian Federation in terms of the structure of cancer incidence per capita and amount to 3,615 new cases for 2021 and 3,925 identified new cases of lung cancer for 2022.

Almost 40-50% of cases of verified lung cancer do not carry a detectable mutational load; accordingly, the targeted use of genetically modified therapy options with an inherent selective effect is not applicable in these cases, but is limited only by a combination of existing chemotherapy regimens, which also have an expected and very limited therapeutic effect. In this regard, in a number of cases, we widely use the technique of loco-regional intra-arterial chemotherapy in the branch of the bronchial artery on the affected side of the right or left lung with an increase in the bioavailability of cytostatics with its local effect and minimal toxic effect in unresectable lung cancer.

TBA